IE
IMDX

Israel Englander’s Insight Molecular Diagnostics IMDX Stock Holding History

Israel Englander’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Sell
82,499
-20,971
-20% -$104K ﹤0.01% 4788
2026
Q1 		$339K Buy
103,470
+42,093
+69% +$244K ﹤0.01% 4954
2025
Q4 		$460K Sell
61,377
-11,914
-16% -$67.2K ﹤0.01% 4998
2025
Q3 		$243K Buy
73,291
+55,781
+319% +$157K ﹤0.01% 5454
2025
Q2 		$52.9K Buy
17,510
+4,106
+31% +$12.4K ﹤0.01% 5609
2025
Q1 		$41K Buy
+13,404
New +$36.2K ﹤0.01% 5562
2023
Q4 		– Sell
-14,754
Closed -$48.4K – 6396
2023
Q3 		$48.4K Sell
14,754
-2,134
-13% -$7.94K ﹤0.01% 5482
2023
Q2 		$77.7K Sell
16,888
-6,848
-29% -$34.5K ﹤0.01% 5383
2023
Q1 		$168K Sell
23,736
-4,332
-15% -$32.2K ﹤0.01% 5243
2022
Q4 		$180K Sell
28,068
-8,001
-22% -$88.2K ﹤0.01% 5372
2022
Q3 		$527K Sell
36,069
-13,739
-28% -$238K ﹤0.01% 4932
2022
Q2 		$896K Buy
+49,808
New +$1.13M ﹤0.01% 4468
2022
Q1 		– Sell
-7,053
Closed -$306K – 7315
2021
Q4 		$306K Sell
7,053
-7,906
-53% -$455K ﹤0.01% 5520
2021
Q3 		$1.06M Sell
14,959
-11,819
-44% -$1.09M ﹤0.01% 4604
2021
Q2 		$3.07M Sell
26,778
-2,461
-8% -$240K ﹤0.01% 3403
2021
Q1 		$3.04M Buy
29,239
+26,352
+913% +$2.5M ﹤0.01% 3123
2020
Q4 		$138K Buy
2,887
+870
+43% +$31.9K ﹤0.01% 4960
2020
Q3 		$56 Buy
+2,017
New +$57.8K ﹤0.01% 4288
2019
Q4 		– Sell
-2,503
Closed -$105K – 4513
2019
Q3 		$105K Sell
2,503
-1,959
-44% -$77K ﹤0.01% 3958
2019
Q2 		$222K Sell
4,462
-6,965
-61% -$579K ﹤0.01% 3705
2019
Q1 		$903K Buy
+11,427
New +$737K ﹤0.01% 2923
2018
Q4 		– Sell
-1,579
Closed -$79K – 4055
2018
Q3 		$79K Sell
1,579
-4,612
-74% -$238K ﹤0.01% 3762
2018
Q2 		$316K Buy
+6,191
New +$305K ﹤0.01% 3367
2017
Q2 		– Sell
-1,317
Closed -$157K – 3740
2017
Q1 		$157K Buy
+1,317
New +$152K ﹤0.01% 3272
2016
Q2 		– Sell
-536
Closed -$49K – 3444
2016
Q1 		$49K Buy
+536
New +$47.5K ﹤0.01% 3153

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Israel Englander's IMDX Position: Q2 2026 in Review

Israel Englander reduced its Insight Molecular Diagnostics (IMDX) stake by 20% in Q2 2026, selling an estimated $104K and leaving 82,499 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #4788.

Israel Englander first reported a position in IMDX in Q1 2016 and has held it in 25 quarters since. The position peaked at $3.07M in Q2 2021. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Israel Englander held 82,499 shares of Insight Molecular Diagnostics worth $487K as of Q2 2026.
  • Israel Englander sold 20,971 Insight Molecular Diagnostics shares in Q2 2026, an estimated $104K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4788 holding.
  • Israel Englander first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 25 quarters since.
  • Israel Englander's Insight Molecular Diagnostics position peaked at $3.07M in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.